AbbVie Ups The Ante For Upadacitinib At EULAR
With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Galapagos is another step closer to commercializing its products with its lead candidate, filgotinib, now under the gaze of EU regulators.
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.